Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients

Hepatology

Volumn 56, Issue 4, 2012, Pages 1261-1270

  Macías, Juan ^a   Berenguer, Juan ^b   Japón, Miguel A ^c   Girón González, José A ^d   Rivero, Antonio ^e   López Cortés, Luis F ^b,c   Moreno, Ana ^f   Márquez, Manuel ^g   Iribarren, José A ^h   Ortega, Enrique ⁱ   Miralles, Pilar ^c   Merchante, Nicolás ^a   Pineda, Juan A ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^e HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^h HOSPITAL DONOSTIA   (Spain)

ⁱ HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDEOXYNUCLEOSIDE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; SAQUINAVIR; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; DISEASE COURSE; FATTY LIVER; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGE DISTRIBUTION; ANALYSIS OF VARIANCE; ANTIVIRAL AGENTS; BIOPSY, NEEDLE; COHORT STUDIES; COINFECTION; CONFIDENCE INTERVALS; DISEASE PROGRESSION; FATTY LIVER; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; LIVER FUNCTION TESTS; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; STATISTICS, NONPARAMETRIC;

EID: 84867215594     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25791     Document Type: Article

References (27)

1. Gaslightwala I, Bini EJ. Impact of HIV infection on the prevalence and severity of steatosis in patients with chronic HCV. J Hepatol 2006; 44: 1026-1032.
2. Castéra L, Loko MA, Le Bail B, Coffie P, De Ledinghen V, Trimoulet P, et al. Hepatic steatosis in HIV-infected patients in France: comparison with HCV-monoinfected patients matched for BMI and genotype. Aliment Pharmacol Ther 2007; 26: 1489-1498.
3. Bani-Sadr F, Carrat F, Bedossa P, Piroth L, Cacoub P, Perronne C, et al. Hepatic steatosis in HIV/HCV-coinfected patients: analysis of risk factors. AIDS 2006; 20: 525-531.
4. McGovern BH, Ditelberg JS, Taylor LE, Gandhi RT, Christopoulos KA, Chapman S, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infections in HIV-seropositive patients. Clin Infect Dis 2006; 43: 365-372.
5. Sterling RK, Contos MJ, Smith PG, Stravitz RT, Luketic VA, Fuchs M, et al. Steatohepatitis: risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. HEPATOLOGY 2008; 47: 1118-1127.
6. Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005; 19: 585-592.
7. Marks KM, Petrovic LM, Talal H, Murray MP, Gulick RM, Glesby MJ. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. J Infect Dis 2005; 192: 1943-1949.
8. Blas-García A, Apostolova N, Ballesteros D, Monleón D, Morales JM, Rocha M, et al. Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. HEPATOLOGY 2010; 52: 115-125.
9. Monto A, Dove LM, Bostrom A, Kakar S, Tien PC, Wright TL. Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection. HEPATOLOGY 2005; 42: 310-316.
10. Neau D, Winnock M, Castéra L, Bail BL, Loko MA, Géraut L, et al. Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV. J Acquir Immune Defic Syndr 2007; 45: 168-173.
11. Rodríguez-Torres M, Govindarajan S, Solá R, Clumeck N, Lissen E, Pessôa M, et al. Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy, and outcomes of anti-HCV therapy: a paired liver biopsy study. J Hepatol 2008; 48: 756-764.
12. Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a metaanalysis of the risk factors. HEPATOLOGY 2010; 52: 71-78.
13. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285.
14. Pascual-Pareja JF, Camino A, Larrauri J, López-Diéguez M, Montes ML, González-García J, et al. Factors associated with hepatic steatosis in human immunodeficiency virus and hepatitis C virus coinfected patients. Med Clin 2009; 132: 208-213.
15. Woreta TA, Sutcliffe CG, Mehta SH, Brown TT, Higgins Y, Thomas DL, et al. Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology 2011; 140: 809-817.
16. McGovern BH. Hepatis steatosis in HIV/HCV-coinfected patients: time to reevaluate! Gastroenterology 2011; 140: 772-775.
17. Macías J, Berenguer J, Japón MA, Girón JA, Rivero A, López-Cortés LF, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. HEPATOLOGY 2009; 50: 1056-1063.
18. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Non-alcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastronterol 1999; 94: 2467-2474.
19. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. HEPATOLOGY 2005; 41: 1313-1321.
20. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-374.
21. Mohanty SR, Troy TN, Huo D, O'Brien BL, Jensen DM, Hart J, et al. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol 2009; 50: 797-804.
22. Maagaard A, Kvale D. Mitochondrial toxicity in HIV-infected patients both off and on antiretroviral treatment: a continuum or distinct underlying mechanisms? J Antimicrob Chemother 2009; 64: 901-909.
23. Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside, and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009; 23: 1109-1118.
24. Fassio E, Alvarez E, Domínguez N, Landeira G, Longo C. Natural history of non alcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. HEPATOLOGY 2004; 40: 820-826.
25. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003; 98: 2042-2047.
26. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
27. Rafiq N, Bai C, Fang Y, Shrishord M, McCullough A, Gramlich T, Younossi ZM. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7: 234-238.